ABSTRACT NUMBER: ESOC2026A1112 THROMBECTOMY PASS NUMBER MODIFIES THE ASSOCIATION BETWEEN INTRA-ARTERIAL ALTEPLASE AND OUTCOMES AFTER SUCCESSFUL REPERFUSION

Abstract Background and aims Despite successful angiographic reperfusion, functional recovery varies. Thrombectomy pass number may reflect procedural complexity and modify the effect of adjunctive intra-arterial alteplase. Methods We conducted a post-hoc exploratory analysis of the PRAEL trial (NCT05856851). Patients were stratified by thrombectomy pass number (<2 vs ≥2) and treatment assignment (intra-arterial alteplase vs standard treatment). The primary outcome was the modified Rankin Scale (mRS) score 0–1 at 90 days, and the safety outcome concluded symptomatic intracranial hemorrhage (sICH) within 36 hours. Results Of the 324 patients, 164 were assigned to intra-arterial alteplase group and 160 to the standard treatment group. Among patients receiving standard medical treatment, mRS 0–1 at 90 days occurred in 36.1% of those with fewer than 2 thrombectomy passes compared with 21.0% of those with 2 or more passes (adjusted risk ratio [RR], 1.73 [95% CI, 0.98–3.04]), while sICH within 36 hours was less frequent in the <2-pass group (1.0% vs 11.3%; adjusted RR, 0.08 [95% CI, 0.01–0.59]). In contrast, among patients treated with intra-arterial alteplase, rates of mRS 0–1 were similar between two groups (48.1% vs 41.5%; adjusted RR, 0.98 [95% CI, 0.61–1.59]), with sICH occurring in 1.2% and 7.3% of patients, respectively. Conclusions Thrombectomy pass number was associated with outcomes and safety under standard medical treatment but not with intra-arterial alteplase. Pass number may therefore help identify patients more likely to benefit from adjunctive intra-arterial thrombolysis. Conflict of interest Jinyuan Wang: nothing to disclose, Yaxuan Pi: nothing to disclose, Yanting Chen: nothing to disclose, Xiaoming Rong: nothing to disclose, Mengqi Liu: nothing to disclose, Qianqing Li: nothing to disclose, Yongteng Xu: nothing to disclose, Songhua Xiao: nothing to disclose, Xinguang Yang: nothing to disclose, Yamei Tang: nothing to disclose.

Authors

Institutions

Publication Details

Journal
European Stroke Journal
Published
2026-05-01
DOI
https://doi.org/10.1093/esj/aakag023.559
Primary Topic
Acute Ischemic Stroke Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ABSTRACT NUMBER: ESOC2026A1112 THROMBECTOMY PASS NUMBER MODIFIES THE ASSOCIATION BETWEEN INTRA-ARTERIAL ALTEPLASE AND OUTCOMES AFTER SUCCESSFUL REPERFUSION

M Liu, Xiaoming Rong, Yaxuan Pi, Yuehua Chen et al.
European Stroke Journal
Acute Ischemic Stroke Management
article

ABSTRACT NUMBER: ESOC2026A1112 THROMBECTOMY PASS NUMBER MODIFIES THE ASSOCIATION BETWEEN INTRA-ARTERIAL ALTEPLASE AND OUTCOMES AFTER SUCCESSFUL REPERFUSION

M Liu, Xiaoming Rong, Yaxuan Pi, Yuehua Chen, Yi-Xiang Wang, Y Xu, Qianqing Li, Songhua Xiao, Xinguang Yang, Yamei Tang
article en

Abstract

Abstract Background and aims Despite successful angiographic reperfusion, functional recovery varies. Thrombectomy pass number may reflect procedural complexity and modify the effect of adjunctive intra-arterial alteplase. Methods We conducted a post-hoc exploratory analysis of the PRAEL trial (NCT05856851). Patients were stratified by thrombectomy pass number (<2 vs ≥2) and treatment assignment (intra-arterial alteplase vs standard treatment). The primary outcome was the modified Rankin Scale (mRS) score 0–1 at 90 days, and the safety outcome concluded symptomatic intracranial hemorrhage (sICH) within 36 hours. Results Of the 324 patients, 164 were assigned to intra-arterial alteplase group and 160 to the standard treatment group. Among patients receiving standard medical treatment, mRS 0–1 at 90 days occurred in 36.1% of those with fewer than 2 thrombectomy passes compared with 21.0% of those with 2 or more passes (adjusted risk ratio [RR], 1.73 [95% CI, 0.98–3.04]), while sICH within 36 hours was less frequent in the <2-pass group (1.0% vs 11.3%; adjusted RR, 0.08 [95% CI, 0.01–0.59]). In contrast, among patients treated with intra-arterial alteplase, rates of mRS 0–1 were similar between two groups (48.1% vs 41.5%; adjusted RR, 0.98 [95% CI, 0.61–1.59]), with sICH occurring in 1.2% and 7.3% of patients, respectively. Conclusions Thrombectomy pass number was associated with outcomes and safety under standard medical treatment but not with intra-arterial alteplase. Pass number may therefore help identify patients more likely to benefit from adjunctive intra-arterial thrombolysis. Conflict of interest Jinyuan Wang: nothing to disclose, Yaxuan Pi: nothing to disclose, Yanting Chen: nothing to disclose, Xiaoming Rong: nothing to disclose, Mengqi Liu: nothing to disclose, Qianqing Li: nothing to disclose, Yongteng Xu: nothing to disclose, Songhua Xiao: nothing to disclose, Xinguang Yang: nothing to disclose, Yamei Tang: nothing to disclose.

European Stroke JournalVol. 11(Supplement_1)
Sun Yat-sen University (CN), Sun Yat-sen Memorial Hospital (CN)
Good health and well-being
Openalex Percentile: Top 9%
Acute Ischemic Stroke Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.